PalindromX Limited (PdX) specialises in developing in vitro diagnostic (IVD) technologies. It is most active in the fields of super-sensitive, multiplexed immunoassay technology, DNA-based vaccination techniques and bone resorption testing services. PdX has generated an intellectual property portfolio in a two areas that is expected to proceed to grant, providing a potentially lucrative future royalty stream. Super sensitive, multiplexed immunoassay; DNA vaccination; bone resorption testing PalindromX Limited (UK) Bone Resorption Services PdX offers a custom in vitro bone resorption testing service to the pharmaceutical, biotechnology and research communities.
Missing: PalindromX's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: PalindromX's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
PalindromX Frequently Asked Questions (FAQ)
When was PalindromX founded?
PalindromX was founded in 2001.
What is PalindromX's latest funding round?
PalindromX's latest funding round is Other Investors.
Who are the investors of PalindromX?
Investors of PalindromX include Liverpool Seed Fund and Merseyside Special Investment Fund.
Who are PalindromX's competitors?
Competitors of PalindromX include Affidea, Novasom, Cardiac Science Corporation, Minomic International, Vivacta and 15 more.
Compare PalindromX to Competitors
Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.
IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.
Clinical Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.
GDXI is a provider of telemedical EKG testing and information services, data management and diagnostic services in the home healthcare and other non-hospital environments.
Zoray Technologies Inc. is developing a multiplex immunoassay platform for life science research and clinical diagnostics. Immunoassays that identify the presence of specific protein biomarkers in blood, urine, or saliva constitute a vital tool in modern healthcare. Zoray's technology aims to enable many immunoassays to be multiplexed on to one small disposable chip. While multiplexed immunoassays are emerging in life science research, existing techniques require a labeling step that adds variability, inhibit high density arrays, and provide a less quantifiable signal. With simple, inexpensive, label-free protein array detection, Zoray expects to make a strong impact in molecular in vitro diagnostics with tests that aim to provide more information than is currently feasible.
Switcher develops and commercializes easy-to-use in vitro diagnostic urine tests
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.